Pharmacogenomics in clinical allergy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The emerging field of pharmacogenomics promises to provide individualized pharmacotherapy based on genotyping. It is relevant for the study of pharmacokinetics, pharmacodynamics, adverse drug reactions, and selection of patients for clinical pharmaceutical trials. There are associated economic, ethical and technological implications. Methods/Data base: Articles were selected from review of MEDLINE, Online Mendelian Inheritance in Man, and the Pharmacogenetics and Pharmacogenomics Knowledge Base. Results: In the discipline of allergy-immunology, specific genes and mutations have been identified for most of the primary immunodeficiency diseases. However, the field of clinical allergy has been less fortunate because of the multiplicity of genes involved, and the potential for multiple gene-environment interactions. In asthma, pharmacogenomics is currently most relevant for the study of beta-2 adrenergic receptor agonists and leukotriene receptor antagonists. However, some pharmaceuticals in development have a very narrow target and will be amenable to this approach. Conclusion: In the next few years, clinical pharmacogenomics will be part of the everyday practice of medicine, including clinical allergy. It will be necessary to use tools of medical informatics in order to assimilate the vast amount of information available from study of the human genome.

Original languageEnglish (US)
Pages (from-to)231-236
Number of pages6
JournalAllergy and Clinical Immunology International
Volume16
Issue number6
DOIs
StatePublished - Nov 1 2004

Fingerprint

Pharmacogenetics
Hypersensitivity
Adrenergic beta-2 Receptor Agonists
Genetic Databases
Leukotriene Antagonists
Medical Informatics
Gene-Environment Interaction
Knowledge Bases
Clinical Medicine
Human Genome
Allergy and Immunology
Drug-Related Side Effects and Adverse Reactions
MEDLINE
Pharmaceutical Preparations
Patient Selection
Genes
Asthma
Pharmacokinetics
Economics
Clinical Trials

Keywords

  • Adverse drug reactions
  • Asthma
  • Disease-related genes
  • Ethics
  • Pharmacogenomics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Pharmacogenomics in clinical allergy. / Dolen, William K.

In: Allergy and Clinical Immunology International, Vol. 16, No. 6, 01.11.2004, p. 231-236.

Research output: Contribution to journalArticle

@article{f7e3b20708954f40a36b93b95c3deb13,
title = "Pharmacogenomics in clinical allergy",
abstract = "Background: The emerging field of pharmacogenomics promises to provide individualized pharmacotherapy based on genotyping. It is relevant for the study of pharmacokinetics, pharmacodynamics, adverse drug reactions, and selection of patients for clinical pharmaceutical trials. There are associated economic, ethical and technological implications. Methods/Data base: Articles were selected from review of MEDLINE, Online Mendelian Inheritance in Man, and the Pharmacogenetics and Pharmacogenomics Knowledge Base. Results: In the discipline of allergy-immunology, specific genes and mutations have been identified for most of the primary immunodeficiency diseases. However, the field of clinical allergy has been less fortunate because of the multiplicity of genes involved, and the potential for multiple gene-environment interactions. In asthma, pharmacogenomics is currently most relevant for the study of beta-2 adrenergic receptor agonists and leukotriene receptor antagonists. However, some pharmaceuticals in development have a very narrow target and will be amenable to this approach. Conclusion: In the next few years, clinical pharmacogenomics will be part of the everyday practice of medicine, including clinical allergy. It will be necessary to use tools of medical informatics in order to assimilate the vast amount of information available from study of the human genome.",
keywords = "Adverse drug reactions, Asthma, Disease-related genes, Ethics, Pharmacogenomics",
author = "Dolen, {William K.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1027/0838-1925.16.6.231",
language = "English (US)",
volume = "16",
pages = "231--236",
journal = "Allergy and Clinical Immunology International",
issn = "0838-1925",
publisher = "Hogrefe Publishing",
number = "6",

}

TY - JOUR

T1 - Pharmacogenomics in clinical allergy

AU - Dolen, William K.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Background: The emerging field of pharmacogenomics promises to provide individualized pharmacotherapy based on genotyping. It is relevant for the study of pharmacokinetics, pharmacodynamics, adverse drug reactions, and selection of patients for clinical pharmaceutical trials. There are associated economic, ethical and technological implications. Methods/Data base: Articles were selected from review of MEDLINE, Online Mendelian Inheritance in Man, and the Pharmacogenetics and Pharmacogenomics Knowledge Base. Results: In the discipline of allergy-immunology, specific genes and mutations have been identified for most of the primary immunodeficiency diseases. However, the field of clinical allergy has been less fortunate because of the multiplicity of genes involved, and the potential for multiple gene-environment interactions. In asthma, pharmacogenomics is currently most relevant for the study of beta-2 adrenergic receptor agonists and leukotriene receptor antagonists. However, some pharmaceuticals in development have a very narrow target and will be amenable to this approach. Conclusion: In the next few years, clinical pharmacogenomics will be part of the everyday practice of medicine, including clinical allergy. It will be necessary to use tools of medical informatics in order to assimilate the vast amount of information available from study of the human genome.

AB - Background: The emerging field of pharmacogenomics promises to provide individualized pharmacotherapy based on genotyping. It is relevant for the study of pharmacokinetics, pharmacodynamics, adverse drug reactions, and selection of patients for clinical pharmaceutical trials. There are associated economic, ethical and technological implications. Methods/Data base: Articles were selected from review of MEDLINE, Online Mendelian Inheritance in Man, and the Pharmacogenetics and Pharmacogenomics Knowledge Base. Results: In the discipline of allergy-immunology, specific genes and mutations have been identified for most of the primary immunodeficiency diseases. However, the field of clinical allergy has been less fortunate because of the multiplicity of genes involved, and the potential for multiple gene-environment interactions. In asthma, pharmacogenomics is currently most relevant for the study of beta-2 adrenergic receptor agonists and leukotriene receptor antagonists. However, some pharmaceuticals in development have a very narrow target and will be amenable to this approach. Conclusion: In the next few years, clinical pharmacogenomics will be part of the everyday practice of medicine, including clinical allergy. It will be necessary to use tools of medical informatics in order to assimilate the vast amount of information available from study of the human genome.

KW - Adverse drug reactions

KW - Asthma

KW - Disease-related genes

KW - Ethics

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=8444227799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444227799&partnerID=8YFLogxK

U2 - 10.1027/0838-1925.16.6.231

DO - 10.1027/0838-1925.16.6.231

M3 - Article

AN - SCOPUS:8444227799

VL - 16

SP - 231

EP - 236

JO - Allergy and Clinical Immunology International

JF - Allergy and Clinical Immunology International

SN - 0838-1925

IS - 6

ER -